AbbVie Inc. Enterprise Value

Enterprise Value of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Enterprise Value growth rates and interactive chart. Calculated as market cap + net debt. A company with a market cap of $1 billion and net cash of $500 million will have an enterprise value of $500 million. Not applicable to financial companies, due to the structure of cash on their balance sheet.

Highlights and Quick Summary

Current Enterprise Value of AbbVie Inc. is $268 Billion (as of December 30, 2020)
  • Enterprise Value for the quarter ending September 29, 2021 was $259 Billion (a -4.91% decrease compared to previous quarter)
  • Year-over-year quarterly Enterprise Value decreased by -3.1%
  • Annual Enterprise Value for 2020 was $268 Billion (a 69.51% increase from previous year)
  • Annual Enterprise Value for 2019 was $158 Billion (a -9.4% decrease from previous year)
  • Annual Enterprise Value for 2018 was $174 Billion (a -5.59% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Enterprise Value of AbbVie Inc.

Most recent Enterprise Valueof ABBV including historical data for past 10 years.

Interactive Chart of Enterprise Value of AbbVie Inc.

AbbVie Inc. Enterprise Value for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $259,401.9 $272,798.16 $267,194.18
2020 $267,703.75 $234,055.71 $243,094.46 $138,741.39 $267,703.75
2019 $157,931.74 $139,895.32 $140,476.0 $151,470.4 $157,931.74
2018 $174,313.79 $175,268.0 $179,362.48 $173,325.86 $174,313.79
2017 $184,641.36 $172,593.83 $145,685.45 $134,763.52 $184,641.36
2016 $131,648.02 $132,290.24 $130,384.84 $115,618.92 $131,648.02
2015 $119,529.0 $112,763.32 $131,691.8 $100,720.3 $119,529.0
2014 $110,979.8 $96,596.2 $94,460.36 $87,289.0 $110,979.8
2013 $88,743.09 $76,333.7 $72,122.29 $72,856.56 $88,743.09
2012 $63,080.24 $63,080.24 $63,080.24 $63,080.24 $63,080.24
2011 $63,080.24 $63,080.24 $63,080.24 $63,080.24 $63,080.24
2010 $63,080.24

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.